Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.
Recruiting
Observational Study
Obesity (Disorder)
Anti-obesity Agents
Precision Medicine
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 220 (estimated)
- Sponsor
- National and Kapodistrian University of Athens · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Obesity is a chronic multifactorial disease with a strong genetic component. Although glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, such as tirzepatide, are highly effective treatments for obesity, substantial inter-individual variability in weight loss response remains. Genetic factors may…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥18 years
* BMI ≥40 kg/m² or ≥37 kg/m² with comorbidities
* Initiation of semaglutide or tirzepatide
Exclusion Criteria:
* Prior bariatric surgery
* Secondary causes of obesity
* Active malignancy
* Chronic pancreatitis
* Family history of medullary thyroid carcinoma
Contacts